Compare CPHC & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | DXR |
|---|---|---|
| Founded | 1994 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 71.4M |
| IPO Year | 2016 | 1995 |
| Metric | CPHC | DXR |
|---|---|---|
| Price | $15.50 | $11.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 994.0 | ★ 12.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,227,000.00 | $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $14.49 | $7.10 |
| 52 Week High | $21.61 | $14.76 |
| Indicator | CPHC | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 41.18 |
| Support Level | $15.06 | $11.31 |
| Resistance Level | $16.02 | $14.02 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 32.89 | 34.35 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.